71 results about "Oral tablets" patented technology

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention relates to the field of biological medicine, in particular to application of quercetagetin in preparation of medicine for preventing hyperuricemia and / or hyperuricemia related diseases. The invention discovers that quercetagetin has a prevention or improvement effect on hyperuricemia and related diseases for the first time. The result of the specific embodiment of the invention shows that the quercetagetin has a good uric acid reducing effect, obviously reduces the activity of uric acid generation participating enzyme, regulates the expression of uric acid transporter mRNA, improves liver injury and kidney injury caused by hyperuricemia, can prevent or relieve hyperuricemia or hyperuricemia-related diseases, and has a good application prospect. The composition can be used for preparing oral tablets and effervescent tablets.

To provide methods for administering RTU injectable preparations of aripiprazole that allows administration to a population of patients considered of having a potential risk for adherence-related relapse or suboptimal treatment outcomes, and allows achievement of therapeutic plasma concentrations without reliance on daily dosing of oral tablets.SOLUTION: The present disclosure is directed to a method for treating a patient with schizophrenia or bipolar disorder Type I by administering to the patient an injectable preparation of aripiprazole, the patient receiving the injectable preparation approximately once every two months.SELECTED DRAWING: None

The present invention discloses a semaglutide oral patch and a preparation method and application thereof, belonging to the field of pharmaceutical preparations. The oral patch comprises the following ingredients: 0.3-0.8 parts of semaglutide, 0.3-0.8 parts of an absorption enhancer, 1-2 parts of a film former and 0.2-0.5 parts of a plasticizer; wherein the film former is composed of hydroxypropyl cellulose, hydroxyethyl cellulose and carboxymethyl cellulose. The oral patch of the present invention has the advantages of high drug loading, high bioavailability, excellent demoulding, mechanical properties, taste and no drug precipitation, and is used to treat type 2 diabetes.

The invention relates to an oridonin-containing microsphere as well as a preparation method and a pharmaceutical preparation thereof, and belongs to the field of oridonin pharmaceutical preparations. The oridonin sustained-release microsphere comprises the following components: oridonin, a water-soluble carrier and a sustained-release carrier, wherein the mass ratio of the oridonin to the water-soluble carrier to the sustained-release carrier is (1-10): (0-10): (3-11). The oridonin-containing microspheres are prepared by stirring and mixing the oil phase containing the oridonin and the sustained-release carrier and the water phase, the preparation operation is simple, and the obtained oridonin-containing microspheres are round in shape, high in entrapment efficiency and capable of better delaying drug release and have an internal net-shaped structure. The microspheres are prepared into oral tablets or capsules, and compared with common in-vivo implanted preparations, the oral tablets or capsules are simpler and more convenient to use, better in physicochemical property, low in production cost and convenient to take and carry.

This utility model discloses a raw material preparation device for oral tablet processing, relating to the field of tablet processing technology. It includes: a device support frame for mounting and fixing a lifting sleeve mechanism, a flow guiding and output mechanism, and a pushing and stirring mechanism; and a lifting sleeve mechanism comprising an outer sleeve slidably disposed vertically inside an upper flow guide hopper and slidably sleeved on the outside of a rotating disk and a sieve plate. Two sets of synchronously moving lifting components are arranged on both sides of the outer sleeve. Each set of lifting components includes an L-shaped side plate fixedly disposed on the side of the worktable, and an electric push rod is fixedly disposed at the bottom of the L-shaped side plate. This utility model can conveniently output large-particle raw materials and prepared raw materials after screening and preparation, saving manpower while effectively improving preparation efficiency. It also provides a more thorough discharge with less residue.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine resistance. The pharmaceutical composition is prepared from active ingredients such as a radix sophorae flavescentis extract, a poria cocos extract, emodin, glucosamine, gambogic acid, tranilast and aspirin. The preparation method of the sophora flavescens extract and the poria cocos extract comprises the steps of raw material pretreatment, dynamic ultrasonic-microwave synergistic extraction, membrane separation and nanofiltration, high-efficiency countercurrent chromatography purification, vacuum low-temperature concentration, drying and the like. The pharmaceutical composition can be prepared into a plurality of pharmaceutical preparations such as tablets, capsules, granules, cream, injections and the like. The invention further provides a preparation method of the oral tablet for reversing pancreatic cancer gemcitabine drug resistance, and the pharmaceutical composition has a remarkable treatment effect on a drug resistance mechanism formed by up-regulating expression of SREBP1 by histone lactylation mediated PKM2 through an AKT / mTOR pathway. The pharmaceutical composition provided by the invention provides a new treatment choice for pancreatic cancer patients, and has an important clinical application value.

The invention discloses a pharmaceutical composition for treating or preventing ovarian cancer, the pharmaceutical composition comprises a PARP inhibitor, a VEGF inhibitor, an excipient, a disintegrating agent, a lubricant and a latent solvent, various raw materials are combined and mixed through a proper process to obtain the pharmaceutical composition for treating ovarian cancer, the PARP inhibitor and the VEGF inhibitor are matched for pharmaceutical production, the formula is novel, and the pharmaceutical composition is suitable for clinical application. The preparation method is simple, the process is ingenious, the growth of the ovarian tumor is synergistically inhibited through multiple mechanisms by utilizing the matched multi-target effect of various inhibitors, the treatment and inhibition effect on the ovarian tumor is improved, the selection and proportioning of auxiliary materials are adopted, the adverse reaction of the medicine is reduced, the workability of medicine granulation is improved, the production is convenient, and the quality of a finished product is ensured; meanwhile, by adopting an oral tablet mode, the traditional Chinese medicine composition has good oral property, the compliance of a patient is improved, and the traditional Chinese medicine composition has a good application prospect.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

This disclosure provides crystalline forms of a compound of Formula (A), and pharmaceutical compositions thereof. This disclosure further provides methods for their preparation and use in methods of treatment, prophylaxis, or delay in onset or progression of HIV infection or AIDS in a subject. This disclosure further provides dosage forms, such as oral tablets, of a compound of Formula (A) and its crystalline forms.

Oral tablet comprising as active principle an association of dry extracts of turmeric, pomegranate and Boswellia, with colonic release, wherein said release is guaranteed by the presence of a combination of sodium alginate and hydroxypropyl methylcellulose in the relative matrix in which the aforementioned active ingredients are dispersed. This oral tablet, preferably in the form of a food supplement, is employed as co-adjuvant in the treatment and prevention of colonic disorders caused by suspected or confirmed alteration of the inflammatory situation and destabilization of the microbiota.

A nano abiraterone acetate composition, a preparation method therefor, and an oral tablet thereof. The composition comprises abiraterone acetate, a suspending aid, a surfactant, and a stabilizer in percentage by weight of 1:(0.1-4):(6-20):(0.01-0.1), and is prepared by wet grinding, drying, and dewatering. The oral bioavailability of the product is improved by adding a cholate absorption-promoting agent, such that the influence of food on drug absorption is reduced.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are methods for making the tablets comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, e.g., comprising slugged tablets, wherein the slugged tablets have greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the slugged tablets meet specifications; target width of 10 to 12 mm, or 11 mm; target weight of approximately 475 to 525 mg; and thickness range of approximately 4 to 6 mm, 4.5 to 5.5 mm or 5 mm. Pharmaceutical composition(s) in the form an oral tablet or capsule comprising N-acetylcysteine amide (NACA) for administration of the pharmaceutical composition to a human.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The invention belongs to the field of medicines, and particularly discloses application of ImP (Imidazole Propionic Acid) in preparation of medicines for preventing or treating metabolic syndrome related diseases, aiming at the problems that the existing anti-obesity medicines are large in side effect, limited in curative effect and the like, and metabonomics research finds that the peripheral blood ImP level in a high-fat diet induced obesity model is remarkably reduced. A zebra fish model (250 [mu] M) and a human fat cell experiment (10-1000 [mu] M) prove that ImP significantly reduces the lipid accumulation rate by more than 40% (Plt; 0.01) of the substrate. The pharmaceutical composition can be prepared into dosage forms such as oral tablets (for example, each tablet containing 50 mg of ImP), sustained-release injections and the like, and can be theoretically combined with orlistat and other medicines for use. Compared with the traditional therapy, the invention reveals the lipid metabolism regulation function of ImP for the first time, and the ImP has the advantages of strong targeting property (IC50 = 120 mu M), high safety (LD50gt; 2000mg / kg) and the like, and a brand new microbial metabolite intervention strategy is provided for obesity and related metabolic diseases.

The invention relates to amitriptyline gel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides amitriptyline gel. The amitriptyline gel is prepared from the following components in parts by mass: 2 to 8 parts of amitriptyline hydrochloride, 16 to 24 parts of glycerol, 2 to 8 parts of hydroxypropyl methylcellulose, 16 to 24 parts of 70 to 80 percent ethanol solution, 0.05 to 0.15 part of ethylparaben, 0.2 to 0.8 part of laurocapram and 36 to 64 parts of water. The amitriptyline gel plaster prepared from the amitriptyline gel can effectively relieve postherpetic neuralgia, and compared with traditional oral tablets, the amitriptyline gel plaster can effectively reduce side effects.

The present invention relates to a pharmaceutical composition comprising ramelteon and a nasal administration formulation. The pharmaceutical composition comprises ramelteon and polyethylene glycol. The pharmaceutical composition of the present invention has high stability and can be used to prepare a pharmaceutical formulation that meets the specifications for nasal administration formulations. Compared with oral tablets, the pharmaceutical composition of the present invention features improved bioavailability of ramelteon and a targeted concentration in brain tissue.

An oral dosage tablet for delivery of hydrophobic active ingredients to a patient and method of forming the same are described. The oral dosage tablet includes one or more layers of an active ingredie

The invention provides an oral tablet. The oral tablet comprises naproxen sodium, mannitol, a super disintegrating agent and a lubricant. The oral tablets described herein do not comprise a glidant (e.g., colloidal silica). These oral tablets may be manufactured using a process of mixing naproxen sodium, mannitol, super disintegrant, and magnesium stearate in a continuous online mixer to form a tableted mixture; transferring the tablet mixture to a tablet press comprising three or more press rollers; and pressing the tableting mixture into the naproxen sodium tablet.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fdlers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

The present application discloses a composition, oral tablets and their preparation method and application, and belongs to the field of food and drug technology. The composition includes sodium sulfate, magnesium sulfate and potassium chloride, and the weight ratio of the sodium sulfate, magnesium sulfate and potassium chloride is (5-10): (1-2): (0.5-1.5); the particle size of the sodium sulfate is less than 700 μm, the purity is not less than 98%, and the moisture content is less than 0.5%; the particle size of the magnesium sulfate is less than 700 μm, the purity is not less than 98.5%, and the moisture content is less than 5.0%; the particle size of the potassium chloride is less than 700 μm, the purity is not less than 98.5%, and the moisture content is less than 1.0%. Each component function is fully exerted, improves the intestinal environment, restores intestinal health, and alleviates functional constipation.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / ml after administration of the pharmaceutical composition to a human.

The present disclosure provides compositions of agglomerated crystalline salts of medium chain fatty acids having improved properties relative to commercially available salts. These salts are useful as excipients in oral dosage forms of medicaments, including as permeation enhancers. This disclosure provides compositions of sodium caprate crystals having improved powder flow and compression behavior. This disclosure further provides oral tablets containing these sodium caprate compositions, including tablets that are substantially free of any compression aid excipient. In various embodiments, these tablets exhibit superior tensile strength and compaction performance than conventional tablets.

Disclosed are formulations in the form of mucoadhesive tablets useful for treating symptoms caused by xerostomia (dry mouth). The tablets according to the invention comprise hyaluronic acid, choline alfoscerate and ascorbyl palmitate, and are characterised by two concave surfaces that adapt to the oral and gingival mucosa so as to adhere to the oral vestibules or the palate.

A semaglutide soluble microneedle composition and a preparation method therefor are disclosed. The soluble microneedle composition comprises a needle material and a base material. The needle material comprises semaglutide and hyaluronidase, and a mass ratio of semaglutide to hyaluronidase is (0.05-172):1. The semaglutide and the hyaluronidase are combined to prepare the soluble microneedle composition, so that the semaglutide can be better promoted to diffuse into the systemic circulation. Compared with a semaglutide oral tablet, the soluble microneedle composition has the advantages that the blood sugar regulating effect is improved by nearly 40 times, the bioavailability of semaglutide is improved, and the dosage and the cost of the hypoglycemic drug are reduced. Moreover, the soluble microneedle technology causes no pain during use and reduces the discomforts of users.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are methods for making the tablets comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, e.g., comprising slugged tablets, wherein the slugged tablets have greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the slugged tablets meet specifications; target width of 10 to 12 mm, or 11 mm; target weight of approximately 475 to 525 mg; and thickness range of approximately 4 to 6 mm, 4.5 to 5.5 mm or 5 mm. Pharmaceutical composition(s) in the form an oral tablet or capsule comprising N-acetylcysteine amide (NACA) for administration of the pharmaceutical composition to a human.

The present disclosure relates to oral naproxen sodium tablets containing roller compacted particles, methods of making the same, and methods of using the same. Naproxen sodium tablets are formulated and prepared by dry granulation, in particular roller compaction. The naproxen sodium tablet is produced by combining a dry granulation compatible excipient with a roller compaction method, and compared with commercially available oral naproxen sodium tablets prepared by a standard wet granulation method, the naproxen sodium tablet has the advantages that the dissolution rate general situation is enhanced, and the disintegration time is shortened.